Denmark
  • Europe
    • FR
    • DE
    • IT
    • ES
    • PL
    • BE
    • NL
    • LU
    • CH
    • NO
    • SE
    • FI
    • EE
    • LV
    • LT
  • Denmark
    • Faroe Islands
    • Greenland
    • Copenhagen
  • Business
    • Mærsk
    • Novo Nordisk
    • DSV
    • Ørsted
    • Danske Bank
    • Vestas Wind Systems
    • LEGO
    • DFDS
  • Nordics
    • Stockholm
    • Oslo
    • Helsinki
  • Baltics
    • Tallinn
    • Riga
    • Vilnius
  • Benelux
    • Brussels
    • Amsterdam
  • Warsaw
  • Berlin
  • NATO
  • UK
  • US
  • Africa
  • Amsterdam
  • Berlin
  • Brussels
  • Copenhagen
  • Danske Bank
  • Denmark
  • DFDS
  • DSV
  • Faroe Islands
  • Greenland
  • Helsinki
  • LEGO
  • Mærsk
  • Novo Nordisk
  • Ørsted
  • Oslo
  • Riga
  • Stockholm
  • Tallinn
  • Vestas Wind Systems
  • Vilnius
  • Warsaw
Denmark
  • Europe
    • FR
    • DE
    • IT
    • ES
    • PL
    • BE
    • NL
    • LU
    • CH
    • NO
    • SE
    • FI
    • EE
    • LV
    • LT
  • Denmark
    • Faroe Islands
    • Greenland
    • Copenhagen
  • Business
    • Mærsk
    • Novo Nordisk
    • DSV
    • Ørsted
    • Danske Bank
    • Vestas Wind Systems
    • LEGO
    • DFDS
  • Nordics
    • Stockholm
    • Oslo
    • Helsinki
  • Baltics
    • Tallinn
    • Riga
    • Vilnius
  • Benelux
    • Brussels
    • Amsterdam
  • Warsaw
  • Berlin
  • NATO
  • UK
  • US
  • Africa

Browsing Tag

Oral presentation

3 posts
NNovo Nordisk
Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig
Read More

Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig

  • 2026-06-26
FRONTIER4 data on investigational denecimig: Exploring efficacy and safety across dosing frequencies for pediatric, adolescent, and adult hemophilia…
NNovo Nordisk
Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
Read More

Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity

  • 2026-05-11
Novo Nordisk A/S Analyses of the higher dose of Wegovy® (semaglutide 7.2 mg) and Wegovy® pill (oral semaglutide…
NNovo Nordisk
Novo Nordisk A/S - share repurchase programme
Read More

Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity

  • 2026-04-28
Novo Nordisk A/S Analyses of the higher dose of Wegovy® (semaglutide 7.2 mg) and Wegovy® pill (oral semaglutide…
Denmark
www.europesays.com